Onconova Therapeutics, Inc.

375 Pheasant Run

Newtown, PA 18954

 

May 15, 2020

 

VIA EDGAR

 

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

 

Attention:	Paul Fischer
	Celeste M. Murphy
Re:	Onconova Therapeutics, Inc.
	Registration Statement on Form S-3
	Filed April 24, 2020
	File No. 333-237844

 

Ladies and Gentlemen:

 

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Onconova Therapeutics, Inc. (the “Company”) hereby requests acceleration of the effective date of the above referenced registration statement, as amended, so that such registration statement may become effective at 4:30 p.m. (Washington, D.C. time) on May 18, 2020, or as soon as practicable thereafter.

 

ONCONOVA THERAPEUTICS, INC.
By:	/s/ MARK GUERIN
	Name:	Mark Guerin
	Title:	Chief Financial Officer